These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 31335389)
1. Biostatistical and Logistical Considerations in the Development of Basket and Umbrella Clinical Trials. Yee LM; McShane LM; Freidlin B; Mooney MM; Korn EL Cancer J; 2019; 25(4):254-263. PubMed ID: 31335389 [TBL] [Abstract][Full Text] [Related]
2. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology. Janiaud P; Serghiou S; Ioannidis JPA Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165 [TBL] [Abstract][Full Text] [Related]
3. An overview of precision oncology basket and umbrella trials for clinicians. Park JJH; Hsu G; Siden EG; Thorlund K; Mills EJ CA Cancer J Clin; 2020 Mar; 70(2):125-137. PubMed ID: 32031692 [TBL] [Abstract][Full Text] [Related]
4. Definitions and statistical properties of master protocols for personalized medicine in oncology. Renfro LA; Mandrekar SJ J Biopharm Stat; 2018; 28(2):217-228. PubMed ID: 28877008 [TBL] [Abstract][Full Text] [Related]
5. National Cancer Institute Basket/Umbrella Clinical Trials: MATCH, LungMAP, and Beyond. Chen AP; Eljanne M; Harris L; Malik S; Seibel NL Cancer J; 2019; 25(4):272-281. PubMed ID: 31335391 [TBL] [Abstract][Full Text] [Related]
6. Basket Trials and the MD Anderson Precision Medicine Clinical Trials Platform. Said R; Tsimberidou AM Cancer J; 2019; 25(4):282-286. PubMed ID: 31335392 [TBL] [Abstract][Full Text] [Related]
7. Novel Study Designs in Precision Medicine - Basket, Umbrella and Platform Trials. Ravi R; Kesari HV Curr Rev Clin Exp Pharmacol; 2022; 17(2):114-121. PubMed ID: 34455953 [TBL] [Abstract][Full Text] [Related]
8. Introduction by the Guest Editor: Oncologic Precision Medicine and the Use of Basket and Umbrella Clinical Trials. Doroshow JH Cancer J; 2019; 25(4):243-244. PubMed ID: 31335387 [No Abstract] [Full Text] [Related]
9. Umbrella and basket trials in oncology: ethical challenges. Strzebonska K; Waligora M BMC Med Ethics; 2019 Aug; 20(1):58. PubMed ID: 31443704 [TBL] [Abstract][Full Text] [Related]
10. Current Statistical Considerations and Regulatory Perspectives on the Planning of Confirmatory Basket, Umbrella, and Platform Trials. Collignon O; Gartner C; Haidich AB; James Hemmings R; Hofner B; Pétavy F; Posch M; Rantell K; Roes K; Schiel A Clin Pharmacol Ther; 2020 May; 107(5):1059-1067. PubMed ID: 32017052 [TBL] [Abstract][Full Text] [Related]
11. Challenges and approaches to implementing master/basket trials in oncology. Burd A; Schilsky RL; Byrd JC; Levine RL; Papadimitrakopoulou VA; Herbst RS; Redman MW; Druker BJ; Gandara DR Blood Adv; 2019 Jul; 3(14):2237-2243. PubMed ID: 31337605 [TBL] [Abstract][Full Text] [Related]
12. Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design. Fountzilas E; Tsimberidou AM; Hiep Vo H; Kurzrock R Cancer Treat Rev; 2024 Apr; 125():102703. PubMed ID: 38484408 [TBL] [Abstract][Full Text] [Related]
13. Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology. Tao JJ; Schram AM; Hyman DM Annu Rev Med; 2018 Jan; 69():319-331. PubMed ID: 29120700 [TBL] [Abstract][Full Text] [Related]
14. Genomic Alteration-Driven Clinical Trial Designs in Oncology. Simon R Ann Intern Med; 2016 Aug; 165(4):270-8. PubMed ID: 27214515 [TBL] [Abstract][Full Text] [Related]
15. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Park JJH; Siden E; Zoratti MJ; Dron L; Harari O; Singer J; Lester RT; Thorlund K; Mills EJ Trials; 2019 Sep; 20(1):572. PubMed ID: 31533793 [TBL] [Abstract][Full Text] [Related]
16. Precision Oncology Clinical Trials: A Systematic Review of Phase II Clinical Trials with Biomarker-Driven, Adaptive Design. Ha H; Lee HY; Kim JH; Kim DY; An HJ; Bae S; Park HS; Kang JH Cancer Res Treat; 2024 Oct; 56(4):991-1013. PubMed ID: 38726510 [TBL] [Abstract][Full Text] [Related]
17. Community-driven development of a modified progression-free survival ratio for precision oncology. Mock A; Heilig CE; Kreutzfeldt S; Huebschmann D; Heining C; Schröck E; Brors B; Stenzinger A; Jäger D; Schlenk R; Glimm H; Fröhling S; Horak P; ESMO Open; 2019; 4(6):e000583. PubMed ID: 31798980 [TBL] [Abstract][Full Text] [Related]
18. Innovative trial design in precision oncology. Tsimberidou AM; Müller P; Ji Y Semin Cancer Biol; 2022 Sep; 84():284-292. PubMed ID: 33022355 [TBL] [Abstract][Full Text] [Related]
19. The New NCI Precision Medicine Trials. Harris LN; Blanke CD; Erba HP; Ford JM; Gray RJ; LeBlanc ML; Hu-Lieskovan S; Litzow MR; Luger SM; Meric-Bernstam F; O'Dwyer PJ; Othus MKD; Politi K; Shepherd LE; Allegra CJ; Chen HX; Ivy SP; Korde LA; Little RF; McShane LM; Moscow JA; Patton DR; Thurin M; Yee LM; Doroshow JH Clin Cancer Res; 2023 Dec; 29(23):4728-4732. PubMed ID: 37531248 [TBL] [Abstract][Full Text] [Related]
20. Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic. Prudkin L; Nuciforo P Cell Oncol (Dordr); 2015 Feb; 38(1):39-48. PubMed ID: 25185990 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]